A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain in routine medical practice in Primary Care settings

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Navarro, Ana ^a   Saldaña, María T ^b   Pérez, Concepción ^c   Torrades, Sandra ^d   Rejas, Javier ^e  

^a Puerta Del Ángel Primary Care Center   (Spain)

^b Primary Care Health Centre Raices   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DICLOFENAC; DIPYRONE; GABAPENTIN; IBUPROFEN; KETOROLAC; PARACETAMOL; PREGABALIN; TRAMADOL; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DRUG DERIVATIVE;

ADULT; ANALGESIA; ARTICLE; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MCGILL PAIN QUESTIONNAIRE; MEDICAL PRACTICE; MONOTHERAPY; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; SPAIN; TRIGEMINUS NEURALGIA; AGED; COST; COST OF ILLNESS; ECONOMICS; HEALTH CARE PLANNING; MIDDLE AGED; NEURALGIA; PRIMARY HEALTH CARE; QUESTIONNAIRE; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADULT; AGED; ANALGESICS; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; NEURALGIA; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SPAIN; TREATMENT OUTCOME;

EID: 78651545088     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-7     Document Type: Article

References (44)

1. IASP Task Force in Taxonomy Pain Terms: A Current List with Definitions and Notes on Usage. Classification of chronic pain syndromes and definitions of pain terms 1994, 206-213. Seattle, Washington: IASP Press, Merksey H, Bogduk N, Second, IASP Task Force in Taxonomy.
2. Jensen TS, Gottrup H, Sindrup SH, et al. The clinical picture of neuropathic pain. Eur J Pharmacol 2001, 429:1-11. 10.1016/S0014-2999(01)01302-4, 11698022.
3. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991, 47:644-666.
4. Smith TE, Chong MS. Neuropathic pain. Hosp Med 2000, 6:760-766.
5. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007, 23:143-149. 10.1097/01.ajp.0000210956.31997.89, 17237663.
6. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005, 30:374-385. 10.1016/j.jpainsymman.2005.04.009, 16256902.
7. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 2007, 23:15-22. 10.1097/01.ajp.0000210945.27052.b3, 17277640.
8. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006, 7:892-900. 10.1016/j.jpain.2006.04.013, 17157775.
9. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006, 10:127-135. 10.1016/j.ejpain.2005.01.014, 16310716.
10. Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 2003, 25(5 Suppl):S12-7. 10.1016/S0885-3924(03)00065-4, 12694988.
11. Rodríguez MJ, García AJ. A Registry of the Aetiology and Costs of Neuropathic Pain in Pain Clinics: Results of the Registry of aEtiologies and Costs (REC) in Neuropathic Pain Disorders Study. Clin Drug Invest 2007, 27:771-782.
12. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006, 20:26-33. 10.1016/j.jdiacomp.2005.09.007, 16389164.
13. Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract 2006, 6:153-160. 10.1111/j.1533-2500.2006.00079.x, 17147591.
14. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35:132-137. 10.1093/ageing/afj048, 16431855.
15. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004, 5:143-149. 10.1016/j.jpain.2003.12.004, 15106126.
16. McCarberg BH, Billington R. Consequences of neuropathic pain: quality-of-life issues and associated costs. Am J Manag Care 2006, 12(9 Suppl):S263-8.
17. Pal S. Prevalence of chronic pain and migraine. Pharmacist 2005, 3:12-15.
18. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005, 118:289-305. 10.1016/j.pain.2005.08.013, 16213659.
19. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007, 29:26-48. 10.1016/j.clinthera.2007.01.013, 17379045.
20. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol 2007, 20:456-472. 10.1097/ACO.0b013e3282effaa7, 17873599.
21. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005, 115:254-263. 10.1016/j.pain.2005.02.032, 15911152.
22. Dworkin RH, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003, 60:1274-1283.
23. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M, . 1008-045 Study Group Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004, 109:26-35. 10.1016/j.pain.2004.01.001, 15082123, 1008-045 Study Group.
24. Stolley PD, Laporte J. The Public Health, the University, and Pharmacoepidemiology. Pharmacoepidemiology 2000, John Wiley & Sons, Strom BL, Third.
25. Gallagher RM. Naturalistic study designs in samples with refractory pain: advantages and limitations. Pain Med 2004, 5:143-145. 10.1111/j.1526-4637.2004.04036.x, 15209966.
26. Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med 2010, 11:719-731. 10.1111/j.1526-4637.2010.00824.x, 20345618.
27. Perez C, Galvez R, Huelbes S, Insausti J, Bouhassira D, Diaz S, Rejas J. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 2007, 5:66. 10.1186/1477-7525-5-66, 2217518, 18053212.
28. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987, 30:191-197. 10.1016/0304-3959(87)91074-8, 3670870.
29. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 1996, 16:231-238. 10.1046/j.1468-2982.1996.1604231.x, 8792034.
30. Vicente-Herrero T, Burke TA, Laínez MJ. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr Med Res Opin 2004, 20:1805-1814. 10.1185/030079904X10151, 15537481.
31. van Leeuwen MT, Blyth FM, March LM, Nicholas MK, Cousins MJ. Chronic pain and reduced work effectiveness: the hidden cost to Australian employers. Eur J Pain 2006, 10:161-166. 10.1016/j.ejpain.2005.02.007, 16310720.
32. Catálogo de Especialidades Farmacéuticas 2006 Consejo General de Colegios Oficiales de Farmacéuticos, Madrid. 2006, Catálogo de Especialidades Farmacéuticas 2006.
33. Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain 2006, 7:119-128. 10.1016/j.jpain.2005.09.004, 16459277.
34. Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007, 23:2585-2596.
35. Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of Pregabalin for the Management of Neuropathic Pain Associated with Diabetic Peripheral neuropathy and Postherpetic Neuralgia: A Canadian Perspective. Clin Ther 2006, 28:1922-1934. 10.1016/j.clinthera.2006.11.017, 17213013.
36. Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg 2008, 63:170-178.
37. O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 2007, 55:1176-1184.
38. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628-638. 10.1016/j.pain.2004.05.001, 15288403.
39. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004, 63:2104-2110.
40. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005, 6:253-260. 10.1016/j.jpain.2004.12.007, 15820913.
41. van Seventer R, Feister HA, Young JP, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006, 22:375-384. 10.1185/030079906X80404, 16466610.
42. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ 2006, 175:265-275. 1513412, 16880448.
43. van der Roer N, Goossens ME, Evers SM, van Tulder MW. What is the most cost-effective treatment for patients with low back pain? A systematic review. Best Pract Res Clin Rheumatol 2005, 19:671-684. 10.1016/j.berh.2005.03.007, 15949783.
44. Collet J, Boivin J. Bias and Confounding in Pharmacoepidemiology. Pharmacoepidemiology 2000, John Wiley & Sons, Strom BL, Third.